Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 0: 200302469, 2003; 10.1373/clinchem.2003.024695
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
clinchem.2003.024695v1
50/1/80    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Howe, J. G.
Right arrow Articles by Smith, B. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Howe, J. G.
Right arrow Articles by Smith, B. R.

Received on July 22, 2003
Accepted on October 30, 2003

Molecular Diagnostics and Genetics

Real-Time Quantitative Reverse Transcription-PCR for Cyclin D1 mRNA in Blood, Marrow, and Tissue Specimens for Diagnosis of Mantle Cell Lymphoma

John Greg Howe 1, Jill Crouch 1, Dennis Cooper 2, Brian R. Smith 3*

1 Department of Laboratory Medicine, Yale University School of Medicine, 333 Cedar St., New Haven, CT 06520
2 Department of Internal Medicine, Yale University School of Medicine, 333 Cedar St., New Haven, CT 06520
3 Departments of Laboratory Medicine and Internal Medicine, Yale University School of Medicine, 333 Cedar St., New Haven, CT 06520

* To whom correspondence should be addressed. E-mail: brian.smith{at}yale.edu.

Background: Overexpression of cyclin D1 mRNA, found in mantle cell lymphoma (MCL), is a critical diagnostic marker. We investigated the use of real-time reverse transcription-PCR (RT-PCR) for cyclin D1.

Methods: We studied 97 fresh specimens (50 blood, 30 bone marrow, 15 lymph node, and 2 other samples) from patients diagnosed with a variety of lymphoproliferative diseases, including 25 cases of MCL. We used real-time quantitative RT-PCR to evaluate cyclin D1 mRNA expression. Because blood and marrow specimens may contain only a minority of potentially malignant cells (as opposed to most lymph nodes) and to increase sensitivity, we normalized the cyclin D1 mRNA concentrations to mRNA of a B-cell-specific marker, CD19, as well as to previously characterized {beta}2-microglobulin mRNA.

Results: In 16 of 21 cases of MCL with overt disease, the ratio of cyclin D1 mRNA to {beta}2-microglobulin mRNA was increased, but all 21 cases showed increased ratios of cyclin D1 mRNA to CD19 mRNA. Cyclin D1 mRNA was low or undetectable in various lymphoproliferative diseases, including cases of ambiguous immunophenotype. The mRNA ratios were stable over 3-7 days of sample storage.

Conclusion: Quantitative RT-PCR for cyclin D1 mRNA normalized to CD19 mRNA can be used in the diagnosis of MCL in blood, marrow, and tissue.© 2004 American Association for Clinical Chemistry


The following articles in journals at HighWire Press have cited this article:


Home page
 J. Clin. Pathol.Home page
R Shakir, N Ngo, and K N Naresh
Correlation of cyclin D1 transcript levels, transcript type and protein expression with proliferation and histology among mantle cell lymphoma
J. Clin. Pathol., August 1, 2008; 61(8): 920 - 927.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Koyanagi, S. J. O'Day, R. Gonzalez, K. Lewis, W. A. Robinson, T. T. Amatruda, C. Kuo, H.-J. Wang, R. Milford, D. L. Morton, et al.
Microphthalmia Transcription Factor as a Molecular Marker for Circulating Tumor Cell Detection in Blood of Melanoma Patients
Clin. Cancer Res., February 15, 2006; 12(4): 1137 - 1143.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Koyanagi, S. J. O'Day, R. Gonzalez, K. Lewis, W. A. Robinson, T. T. Amatruda, H.-J. Wang, R. M. Elashoff, H. Takeuchi, N. Umetani, et al.
Serial Monitoring of Circulating Melanoma Cells During Neoadjuvant Biochemotherapy for Stage III Melanoma: Outcome Prediction in a Multicenter Trial
J. Clin. Oncol., November 1, 2005; 23(31): 8057 - 8064.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
K. Koyanagi, C. Kuo, T. Nakagawa, T. Mori, H. Ueno, A. R. Lorico Jr, H.-J. Wang, E. Hseuh, S. J. O'Day, and D. S.B. Hoon
Multimarker Quantitative Real-Time PCR Detection of Circulating Melanoma Cells in Peripheral Blood: Relation to Disease Stage in Melanoma Patients
Clin. Chem., June 1, 2005; 51(6): 981 - 988.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2003 by the American Association for Clinical Chemistry.